BioCentury
ARTICLE | Company News

Achaogen furnishes data for Pew antibiotic platform targeting Gram-negative bacteria

October 26, 2018 4:59 PM UTC

Achaogen Inc. (NASDAQ:AKAO) gave data from a discontinued program to The Pew Charitable Trusts' Shared Platform for Antibiotic Research and Knowledge (SPARK), an open-access platform launched last month. Pew Senior Officer Wes Kim told BioCentury that Achaogen is the first company to do so.

Pew's SPARK aims to accelerate basic research concerning barriers to discovering new antibiotics for Gram-negative bacterial infections. Achaogen's data came from its bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC) inhibitor program for the indication; it discontinued that program last year on toxicity findings. SPARK will receive Achaogen's scientific and technical data about LpxC structure, function and physical materials, the biotech told BioCentury...